Who are Osphena's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Clorotrisin, Depoestradiol, Demethylchlortetracycline, Estradiol + Progesterone, Estradiol 0.01% Vag Cream, Bazedoxifene/Conjugated Estrogen.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ospemifene.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Osphena — Competitive Intelligence Brief

Osphena (OSPEMIFENE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Estrogen Agonist/Antagonist [EPC]. Area: Other.

marketed Estrogen Agonist/Antagonist [EPC] Estrogen receptor beta Other Small molecule Live · refreshed every 30 min

Target snapshot

Osphena (OSPEMIFENE) — Duchesnay. Osphena works by binding to estrogen receptors, specifically targeting estrogen receptor beta, to provide relief from symptoms of atrophic vulva and dyspareunia.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Osphena TARGET	OSPEMIFENE	Duchesnay	marketed	Estrogen Agonist/Antagonist [EPC]	Estrogen receptor beta	2013-01-01
Clorotrisin	CHLOROTRIANISENE		marketed	chlorotrianisene	Estrogen receptor, Estrogen receptor beta	1982-01-01
Depoestradiol	ESTRADIOL CYPIONATE	Pfizer	marketed	Estrogen	Estrogen receptor beta	1979-01-01
Demethylchlortetracycline	DEMECLOCYCLINE	Pfizer	marketed	Tetracycline-class Antimicrobial	Estrogen receptor beta	1960-01-01
Estradiol + Progesterone	Estradiol + Progesterone	Productos Científicos S. A. de C. V.	marketed	Hormone replacement therapy / Oral contraceptive	Estrogen receptor alpha (ERα), Estrogen receptor beta (ERβ), Progesterone receptor (PR)
Estradiol 0.01% Vag Cream	Estradiol 0.01% Vag Cream	TriHealth Inc.	marketed	Estrogen receptor agonist	Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ)
Bazedoxifene/Conjugated Estrogen	Bazedoxifene/Conjugated Estrogen	University of North Carolina, Chapel Hill	marketed	Selective Estrogen Receptor Modulator (SERM) combined with Conjugated Estrogens	Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Estrogen Agonist/Antagonist [EPC] class)

Duchesnay · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Osphena — Competitive Intelligence Brief. https://druglandscape.com/ci/ospemifene. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab